Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IrniCann
- Development stage
- Preclinical
- Lead developer
- Argent BioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**IrniCann** is an Argent BioPharma preclinical oncology candidate for glioblastoma multiforme. Argent BioPharma describes the program as targeting glioblastoma tumor cells and glioblastoma stem cells; reported preclinical findings include reduced cell viability, cytotoxicity, and caspase-dependent apoptosis. A third-party pipeline catalog identifies IrniCann as a cannabidiol plus cannabigerol combination, although Argent BioPharma's public materials reviewed do not disclose a detailed composition, dose, route, or direct molecular target profile. ([cphi-online.com](https://www.cphi-online.com/product/irnicann/))
- Other names
- IrniCann
Beyond the preview
Go deeper on IrniCann.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IrniCann.